Abstract
A new series of imidazopyridine CB2 agonists is described. Structural optimization improved CB2/CB1 selectivity in this series and conferred physical properties that facilitated high in vivo exposure, both centrally and peripherally. Administration of a highly selective CB2 agonist in a rat model of analgesia was ineffective despite substantial CNS exposure, while administration of a moderately selective CB2/CB1 agonist exhibited significant analgesic effects.
Copyright © 2011 Elsevier Ltd. All rights reserved.
MeSH terms
-
Analgesics / chemical synthesis
-
Analgesics / chemistry*
-
Analgesics / therapeutic use
-
Animals
-
Disease Models, Animal
-
Freund's Adjuvant / pharmacology
-
Humans
-
Hyperalgesia / drug therapy
-
Pyridines / chemical synthesis
-
Pyridines / chemistry*
-
Pyridines / therapeutic use
-
Rats
-
Receptor, Cannabinoid, CB1 / agonists*
-
Receptor, Cannabinoid, CB1 / metabolism
-
Receptor, Cannabinoid, CB2 / agonists*
-
Receptor, Cannabinoid, CB2 / metabolism
Substances
-
Analgesics
-
Pyridines
-
Receptor, Cannabinoid, CB1
-
Receptor, Cannabinoid, CB2
-
Freund's Adjuvant
-
pyridine